Orforglipron (30mg/50mg)
Oral, Non-Peptide GLP-1 Receptor Agonist
Orforglipron is listed for non-peptide GLP-1 research. Catalog vial contents are 30mg / 50mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Orally bioavailable, no injection required
- Non-peptide chemistry resistant to GI degradation
- No food or water-volume restrictions vs oral semaglutide
- Investigational obesity & T2D research compound
What is Orforglipron?
Orforglipron, also called LY3502970, is a small-molecule GLP-1 receptor agonist, not a peptide. This catalog offers 30mg and 50mg research vials. A laboratory vial is not the oral formulation studied clinically.
Listed vial contents: 30mg / 50mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Orforglipron activates GLP-1 receptors using non-peptide chemistry. Researchers can compare small-molecule and peptide receptor responses in controlled assays. Chemical class and formulation must both be considered when interpreting results.
What are the research questions?
- Small-molecule versus peptide GLP-1 receptor pharmacology
- Formulation-dependent behavior
- Separating cell-based receptor responses from clinical endpoints
What does the published work describe?
Wharton and colleagues' 2023 phase 2 trial studied an oral formulation in adults with obesity. Frías and colleagues' separate phase 2 trial studied adults with type 2 diabetes. These are human clinical studies of defined preparations, not evidence that a research vial is suitable for administration.
Experimental models in the cited papers
- Randomized phase 2 human obesity trial
- Randomized phase 2 human type 2 diabetes trial
What could future research explore?
Small-molecule GLP-1 activity opens questions about receptor interactions and formulation development. Potential future applications depend on evidence for a characterized preparation, not on its availability as a research reagent.
These are research directions, not established applications of the product sold here.
What are the limits of this evidence?
Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.
Study references
- Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023. PMID 37351564
- Frías JP, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023. PMID 37369232
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Orforglipron handled in the lab?
For Orforglipron, record the product code ORFO-30, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Orforglipron is not a peptide. Select solvent, pH and working conditions from documentation for the specific chemical form and the assay, not a generic peptide reconstitution recipe. Test a small portion, check for precipitation after dilution into assay medium and include vehicle controls.
For Orforglipron, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 600.66 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Orforglipron form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Orforglipron laboratory protocol should record identity, product code ORFO-30, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Orforglipron
- CAS Number
- 2212020-52-3
- Molecular Weight
- 600.66 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $189.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Orforglipron has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Orforglipron?
Orforglipron is listed for non-peptide GLP-1 research. Catalog vial contents are 30mg / 50mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Orforglipron are available?
The catalog lists 30mg / 50mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Orforglipron purity results?
Orforglipron has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Orforglipron be handled in the laboratory?
For Orforglipron, record the product code ORFO-30, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Orforglipron?
Orforglipron is not a peptide. Select solvent, pH and working conditions from documentation for the specific chemical form and the assay, not a generic peptide reconstitution recipe. Test a small portion, check for precipitation after dilution into assay medium and include vehicle controls.
How do I calculate a Orforglipron stock concentration?
For Orforglipron, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 600.66 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Orforglipron be stored after preparation?
Use the documented storage conditions for the supplied Orforglipron form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Orforglipron lab protocol document?
A Orforglipron laboratory protocol should record identity, product code ORFO-30, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Orforglipron product?
Orforglipron is a non-peptide research material; Fmoc/Boc peptide synthesis is not its default manufacturing model. Review compound-specific identity and impurity methods rather than assigning peptide sequence or synthesis claims to this product.
Is Orforglipron for human use?
No. Orforglipron is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
